Overview
A Phase Ib Study of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer
Status:
Unknown status
Unknown status
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
Brief Description: This study is designed to evaluate the safety and tolerability of oral Selatinib Ditosilate Tablets, and explore the maximum tolerated dose (MTD) and dose-limiting toxicity in patients with advanced breast cancer.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.
Criteria
Inclusion Criteria:- women aged 18-65.
- Patients with ECOG performance status of 0 or 1.
- Expected life-expectancy of more than 3 months.
- Patients must have histologically or cytologically confirmed breast cancer. Either the
primary breast tumor or the metastasis must overexpress HER2; acceptable methods of
measurement of HER2 expression include immunohistochemistry (IHC) and fluorescence in
situ hybridization (FISH); tumors tested by IHC must be 3+ positive for HER2
overexpression immunohistochemistry ; tumors tested by FISH must be positive.
- Prior Herceptin therapy is discontinued because of disease progression or patients can
not afford for Herceptin therapy.
- patients with at least one measurable lesion (RECIST1.1 criteria).
- Hematology: WBC≥3.5×109/L, ANC≥1.5×109/L, PLT≥100×109/L,HB≥90g/L;
- Biochemistry: Serum bilirubin≤1.5 times upper limit of normal (ULN),AST and ALT ≤1.5
times ULN; creatinine and urea nitrogen≤1.5 times ULN; LVEF≥50%, ECG normal, and
Fridericia corrected QT(QTcF)<470ms.
- patients receiving damage caused by other therapeutic has been restored, the interval
more than six weeks since the last receiving nitroso or mitomycin; more than 4 weeks
since last receiving radiotherapy, other cytotoxic drugs or surgery.
- Subjects can swallow and have normal gastrointestinal function.
- Female subjects should agree to take contraceptives during the study and within 6
months after the study (such as intrauterine device [IUD], contraceptive drugs or
condoms); within 7 days before they enter the study, their serum or human chorionic
gonadotropin should be negative, and must be in the non-lactation period.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Patients have uncontrolled large pleural effusion and ascites.
- Patients have received steroid for more than 50 days, or requiring for steroid therapy
for a long time.
- Requirement for the therapeutic drugs prolonging QT interval(such as anti-arrhythmia
drugs), and can not interrupt them.
- Patients with a history of symptomatic brain metastases.
- Patients have received small molecule targeted drug therapy of inhibition of HER-2 or
EGFR.
- Patients have participated in other drug clinical research in the past 4 weeks.
- Pregnant or lactating women are excluded from this study.
- Patients with a history of allergic reactions attributed to compounds of similar
chemical composition to the agents used in the study are ineligible;
- Patients with active infection ;
- Patients with cardiac disease including Angina, any significant or need to be treated
arrhythmia,Myocardial infarction, Heart failure, LVEF<45%, other heart diseases that
are not suitable for participating in the study judged by investigator.
- Patients with other concurrent severe and/or uncontrolled medical conditions
(including hypertension, severe diabetes, thyroid disease, etc.) that could cause
unacceptable safety risks or compromise compliance with study requirements are
ineligible.
- Patients with a history of mental disorders, including epilepsy or dementia are
ineligible.